MicroRNA Market Report 2026

The microrna market size has grown rapidly in recent years. It will grow from $1.57 billion in 2025 to $1.86 billion in 2026 at a compound annual growth rate (CAGR) of 18.5%. The growth in the historic period can be attributed to rise in genomic research adoption, increasing demand for biomarker discovery, growth of pcr-based testing, expansion of cancer research programs, rising use of ngs instruments.

The microrna market size is expected to see rapid growth in the next few years. It will grow to $3.32 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to increasing clinical applications of microrna diagnostics, rise in personalized medicine usage, growth in therapeutic microrna development, expansion of infectious disease research, rising investments in molecular assay technologies. Major trends in the forecast period include expansion of precision genomics, AI-driven microrna expression analysis, growth in cloud-based sequencing data storage, automation in molecular diagnostics, iot-enabled laboratory workflow integration.

The rising incidence of cancer is anticipated to drive the growth of the microRNA market in the coming years. Cancer is a complex disease marked by uncontrolled cell growth and proliferation, often resulting in malignant tumors that can invade nearby tissues and spread to distant organs, creating serious health concerns. The growing number of cancer cases is attributed to several factors, including aging populations, lifestyle habits such as smoking and unhealthy diets, exposure to environmental pollutants, and advancements in detection techniques that enable earlier diagnosis. MicroRNA is increasingly used alongside conventional cancer therapies to improve drug sensitivity and enhance treatment outcomes. In addition to therapeutic applications, miRNAs function as diagnostic and prognostic biomarkers, supporting the identification of cancer types, forecasting disease progression, and monitoring responses to treatment. For example, in May 2024, according to the National Cancer Institute, a US-based government agency, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022, with projections indicating that annual figures could reach 29.9 million new cases and 15.3 million deaths by 2040. Consequently, the growing burden of cancer is fueling the expansion of the microRNA market.

Leading companies operating in the microRNA market are concentrating on the development of advanced offerings, such as miRNA probe customization services, to address the specific requirements of researchers and clinicians, improve the precision of miRNA detection, and support a broad range of applications. MiRNA probe customization services involve specialized solutions provided by biotechnology and molecular biology companies to design and manufacture probes tailored to specific microRNAs for use in research and clinical settings. For instance, in September 2023, Abnova Corporation, a Taiwan-based biotechnology company, introduced upgraded miRNA probe customization services along with an expanded portfolio of catalog miRNA probes to serve the varied needs of academic, industrial, and research organizations involved in miRNA studies. These probes are essential for accurately identifying and localizing miRNAs, which are small, non-coding RNA molecules that play critical roles in numerous biological processes. Abnova’s customization services offer high specificity and reduced cross-reactivity, making them suitable for analyzing samples with low miRNA abundance.

In May 2024, Bruker Corporation, a US-based scientific instruments company, acquired NanoString Technologies Inc. for approximately $392.6 million. Through this acquisition, Bruker seeks to strengthen its expertise in gene expression profiling and spatial transcriptomics, thereby reinforcing its position within the life sciences research sector. NanoString Technologies Inc. is a US-based biotechnology company that specializes in delivering solutions for gene expression analysis.

Major companies operating in the microrna market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Miltenyi Biotec, LGC Limited, Promega Corporation, Abcam plc, Integrated DNA Technologies Inc., NanoString Technologies Inc., Horizon Discovery Ltd., OriGene Technologies Inc., Omega Bio-Tek, New England Biolabs, Quantabio, SeqMatic LLC, GeneCopoeia Inc., HTG Molecular Diagnostics Inc.

North America was the largest region in the microRNA market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the microrna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microrna market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on laboratory instruments, sequencing components, and biochemical reagents have increased the cost of manufacturing and importing microRNA testing systems, particularly affecting research-dependent regions such as North America and Europe. These tariffs disrupt supply chains, delay procurement, and create pricing challenges for academic and diagnostic laboratories. However, the pressure has encouraged local reagent production and innovation in cost-effective assay development, partially offsetting the negative impact.

The microrna market research report is one of a series of new reports that provides microrna market statistics, including microrna industry global market size, regional shares, competitors with a microrna market share, detailed microrna market segments, market trends and opportunities, and any further data you may need to thrive in the microrna industry. This microrna market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

MicroRNAs are small, non-coding RNA molecules, generally around 20-22 nucleotides long, that play a role in regulating gene expression. They act by binding to complementary sequences on messenger RNA (mRNA) molecules, which typically leads to gene silencing through translational inhibition or degradation of the target mRNA.

The primary microRNA products include instruments and consumables. MicroRNA instruments encompass the tools and equipment used for microRNA analysis, such as microarray scanners and PCR machines. The different assay types include immunoassays, next-generation sequencing, miRNA arrays, and polymerase chain reaction (PCR)-based arrays, which are utilized in cancer, infectious diseases, immunological disorders, cardiovascular diseases, neurological diseases, and other applications by academic and research institutes, biopharmaceutical companies, diagnostic centers, and clinical research organizations.

The microRNA market consists of revenues earned by entities by providing services such as microRNA sequencing and data analysis services, microRNA therapeutic development services, and microRNA profiling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The microRNA market also includes sales of microRNA extraction kits, microRNA detection kits, microRNA quantification kits, and microRNA expression arrays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.